Drugs / Epetraborole
Epetraborole
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05995444 | Jun → Jul 2023 | — | AN2 Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05283746 | Feb → Jun 2022 | impaired renal function disease | AN2 Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04892641 | Jun 2021 → Feb 2022 | — | AN2 Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01495065 | Dec 2011 → Feb 2012 | infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01702350 | Oct → Dec 2011 | infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01475695 | Apr → May 2011 | infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01267968 | Jan → Mar 2011 | infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01262885 | Oct 2010 → Aug 2011 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07301320 | Mar 2026 → Dec 2027 expected | pulmonary non-tuberculous mycobacterial infection | Kevin Winthrop | Recruiting | No outcome recorded |
| Phase 2 | NCT01381562 | Oct 2011 → Mar 2012 | intestinal infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT01381549 | Jun 2011 → Mar 2012 | urinary tract infection | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT05327803 | May 2022 → Dec 2024 | Mycobacterium avium complex disease | AN2 Therapeutics, Inc | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01015014 Comparator | Nov 2009 → May 2010 | gram-negative bacterial infections | Pfizer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-31 | AN2 Therapeutics, Inc | Results AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting an2therapeutics.com ↗
Clinical and nonclinical studies demonstrated potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters. |
| 2026-01-12 | AN2 Therapeutics, Inc | Regulatory AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease an2therapeutics.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epetraborole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05327803 ↗ |
| Known as | (S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride | “GSK2251052 ((S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride) is a Gram negative antibacterial compound currently in development...” NCT01262885 ↗ |
| Known as | AN3365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01015014 ↗ |
| Known as | EBO | “Epetraborole (EBO), a boron-containing heterocycle also possessing amine and hydroxyl functional groups” NCT07301320 ↗ |
| Known as | Epetraborol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3549142 ↗ |
| Known as | GSK2251052 | “GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA” NCT01267968 ↗ |
| Action | Inhibit | “inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS)” NCT01267968 ↗ |
| Modality | Small molecule | “a boron-containing heterocycle” NCT07301320 ↗ |
| Route | Oral | “single oral doses” NCT01262885 ↗ |